Sun, Dec 21, 2014, 4:02 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Synta Pharmaceuticals Corp. (SNTA) Message Board

pharmatheway 78 posts  |  Last Activity: Dec 19, 2014 3:26 PM Member since: May 4, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • pharmatheway pharmatheway Dec 19, 2014 3:26 PM Flag

    I'm glad i was wrong.And i never said anything about selling it was JMHO that i posted.

    Sentiment: Buy

  • pharmatheway pharmatheway Dec 19, 2014 11:43 AM Flag

    If it breaks below 15 you could see low 14s or even high 13s before moving up again .JMHO

    Sentiment: Buy

  • Reply to

    Not so good.

    by pharmatheway Dec 17, 2014 4:03 PM
    pharmatheway pharmatheway Dec 18, 2014 11:08 AM Flag

    I agree .Not sure of the bottom yet unfortunately.

    Sentiment: Hold

  • pharmatheway by pharmatheway Dec 17, 2014 4:03 PM Flag

    Not a good close on a green day .IMO

    Sentiment: Buy

  • Reply to

    Obamas amnesty struck down

    by aint_livin_off_me Dec 16, 2014 4:27 PM
    pharmatheway pharmatheway Dec 17, 2014 3:58 PM Flag

    246 toothpicks on the floor, 4 in box, 1 in his hand = 251 LOL

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 17, 2014 11:28 AM Flag

    Listen son people did not sacrifice life and limb for this country for the sake of it not being the greatest country in the world.That is our history we do not torture ,we do not lower ourselves to their level,we are strong and proud ,we are americans.

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 17, 2014 10:38 AM Flag

    Tom Ridge said.If America is a product, our value system is our brand, Ridge said. Extreme torture tactics, such as waterboarding — branded “enhanced interrogation techniques” by the Bush administration — do not comply with that brand.

    “Whether we like it or not, we are held to a higher standard because we are America,” Ridge said. “It’s a fact, at least in my mind. And we need to stay true to that standard.”

    Sentiment: Strong Buy

  • Reply to

    PHASE 3 TRIALS BEGIN ANY DAY NOW!!

    by golderw3 Dec 16, 2014 8:53 PM
    pharmatheway pharmatheway Dec 17, 2014 10:06 AM Flag

    Also this :TG-1101 + Ibrutinib Phase 3 Study Program - The GENUINE Trial

    As previously announced, TG Therapeutics, Inc. has reached an agreement with the U.S. Food and Drug Administration (FDA) regarding a Special Protocol Assessment (SPA) on the design, endpoints and statistical analysis approach of a Phase 3 clinical trial for TG-1101 (ublituximab), its glycoengineered anti-CD20 monoclonal antibody, in combination with Imbruvica® (ibrutinib) for the treatment of Chronic Lymphocytic Leukemia (CLL) in patients with high risk cytogenetics. The SPA provides agreement that the Phase 3 trial design adequately addresses objectives that would support the regulatory submission for drug approval.

    The GENUINE phase 3 trial is a randomized controlled clinical trial, with patients receiving either TG-1101 plus ibrutinib or ibrutinib alone. The trial will enroll approximately 330 patients, with approximately the first two-thirds of the patients included in the ORR assessment. As per the SPA, the Company plans to use the ORR data from the trial as the basis for submission of a Biologics License Application (BLA) for accelerated approval for TG-1101. All patients will then be followed for progression free survival (PFS) assessment, which is designed to support full approval.

    Sentiment: Strong Buy

  • Reply to

    PHASE 3 TRIALS BEGIN ANY DAY NOW!!

    by golderw3 Dec 16, 2014 8:53 PM
    pharmatheway pharmatheway Dec 17, 2014 9:29 AM Flag

    Just go to clinical trials .gov and search T G Therapeutics .Its that simple.

    Sentiment: Strong Buy

  • Reply to

    Why would anyone take profits? Many reasons...

    by storytime617 Dec 15, 2014 11:02 AM
    pharmatheway pharmatheway Dec 15, 2014 11:26 AM Flag

    We had people like you saying the same bull when PCYC was trading at $5.00 and $15.00 and all the way up over $100.00.If i sold PCYC every time some person who is short made a dumb statement like you have i would have lost a large profit that i made.And i will make more with this company.People like Jeff P. Sharman, MD , Dr. Susan O'Brien and MD Anderson know what they are doing.So know you will be on ignore for posting nonsense.P.S. No insider selling here.

    Sentiment: Strong Buy

  • Reply to

    Elizabeth Has A Good Point

    by speedydekker Dec 11, 2014 8:22 AM
    pharmatheway pharmatheway Dec 11, 2014 8:03 PM Flag

    So we've learned nothing since the economic crash. Big business still gets to play roulette investors' money. I'm guessing the government will bail them out.

    Spin this #$%$ any way you want, many of our politicians care nothing about those in the middle or bottom income levels. They'll spend billions to keep terrorists from blowing up a building while Wall Street Raiders bring the economy to a standstill. You call this government? I call it plutocracy.

    Sentiment: Strong Buy

  • Reply to

    Rumors

    by starfe1l Dec 11, 2014 11:40 AM
    pharmatheway pharmatheway Dec 11, 2014 12:36 PM Flag

    Yes it is .Michael S. Weiss did say if the right offer came along ,well you know the rest..

    Sentiment: Strong Buy

  • WEDNESDAY, DECEMBER 3, 2014

    ASCO 2014: Dr. Susan O'Brien Outlines Open Trials of Novel Agents and Equipoise in Trial Design for CLL (chronic lymphocytic leukemia)
    In the third part of my interview at ASCO 2014, Dr. O'Brien points out the advantages of being in a clinical trial, including the real financial advantages of getting the trial drug for free. However do remember that the standard of care of drugs such as rituximab are not free. The labs and imaging are not usually free.

    The one exemption are trials at the NIH where all costs are paid by our tax dollars. This is is the only way that most of those with no insurance or from out of country can afford to be in a clinical study.

    Some of the active trials Dr. O'Brien asks us to consider is the phase 1 trial of the very promising second generation BTK inhibitor, ACP-196 that seems to be more selective and has longer binding. Nothing published yet, the early buzz is positive

    TG Therapeutics has its next generation anti CD-20 monoclonal antibody and its PI3K inhibitor combined in a promising trial.

    The CLL arm of trial of "Ublituximab + Ibrutinib in Select B-cell Malignancies" is already closed.

    There is an ibrutinib versus ibrutinib plus rituximab trial at MD Anderson for relapsed patients. Free ibruinib!

    The list keeps growing. Please check out clinicaltrials.gov when you are considering therapy. We need more options and the only way we get them is through trials, and the only way trials happen is if patients enroll (and their doctors recommend them).

    Finally Dr. O'Brien eloquently addresses the issue of equipoise in clinical trials. This ASCO post article from 2013 should be mandatory reading for all patients and all trialists. Please listen carefully to all that she has to say, and how these breakthrough medication have changed how we should design future research. There are lives in the balance.

    Sentiment: Strong Buy

  • www.watchlistnews.com/tg-therapeutics-pt-raised-to-33-00-at-roth-capital-tgtx/179482/

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 8, 2014 2:49 PM Flag

    Dr. Jeff Sharman, Medical Director of Hematology Research for the US Oncology Network, and Study Chair for the Phase 2 trial stated: "We continue to be impressed with the clinical activity and safety profile of ublituximab in combination with ibrutinib, especially in the high-risk CLL patient group which we will be evaluating in the upcoming Phase 3 trial. This data not only shows ublituximab can be safely combined with ibrutinib, but also can induce rapid and deeper responses compared to prior trials of ibrutinib alone. I am very excited, along with the team of investigators at US Oncology, to lead the upcoming Phase 3 trial and believe it will be an attractive protocol with great interest from patients for this study."

    Sentiment: Strong Buy

  • pharmatheway by pharmatheway Dec 8, 2014 10:50 AM Flag

    Dec 8, 2014
    10:45 PM ET TG Therapeutics' 2014 Analyst & Investor Event
    webcast

    Sentiment: Strong Buy

  • Reply to

    Just out

    by golderw3 Dec 6, 2014 7:55 PM
    pharmatheway pharmatheway Dec 7, 2014 10:39 AM Flag

    we believe the single agent profile of TGR-1202 positions it well as an ideal agent for combination therapy, especially in combination with our proprietary, glycoengineered anti-CD20 monoclonal antibody, TG-1101 for which preliminary data will be presented on Tuesday morning."

    Sentiment: Strong Buy

  • pharmatheway by pharmatheway Dec 6, 2014 10:20 AM Flag

    Presentations on TG-1101 and TGR-1202 at the ASH meeting include the following:

    Oral Presentation:

    Title: Ublituximab, A Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mAb), In Combination With TGR-1202, A Next Generation Once Daily PI3k delta Inhibitor, Demonstrates Activity In Heavily Pre-Treated And High-Risk CLL And B-Cell Lymphoma
    Oral Session: 801
    Session: 624. Lymphoma: Therapy with Biologic Agents, excluding Pre-Clinical Models: Indolent B-cell NHL and T-cell NHL
    Date and Time: Tuesday, December 9, 2014 at 8:00am, during 7:30 - 9:00 AM PT Session
    Location: West Building, 2005-2007-2018-202
    Presenter: Matthew Lunning, DO
    Clinical Posters:

    Title: TGR-1202, A Novel Once Daily PI3K delta Inhibitor, Demonstrates Clinical Activity With A Favorable Safety Profile, Lacking Hepatotoxicity, In Patients With CLL And B-Cell Lymphoma
    Abstract Number: 1984
    Session: 642. CLL: Therapy, excluding Transplantation: Poster I
    Date and Time: Saturday, December 6, 2014: 5:30 PM- 7:30 PM PT
    Location: West Building, Level 1
    Presenter: Howard A. Burris III, MD
    Title: Ublituximab (TG-1101), A Novel Glycoengineered Anti-CD20 Monoclonal Antibody, In Combination With Ibrutinib Is Highly Active In Patients With Relapsed and/or Refractory CLL And MCL; Results Of A Phase II Trial
    Abstract Number: 4679
    Session: 642. CLL: Therapy, excluding Transplantation: Poster III
    Date and Time: Monday, December 8, 2014: 6:00 PM- 8:00 PM PT
    Location: West Building, Level 1
    Presenter: Jeff P. Sharman, MD
    Pre-Clinical Posters:

    Title: Complementary Targeting of PI3K and the Proteasome Causes Potent Inhibition of mTORC1 and NF-KappaB in Models of B- and T-Cell Lymphoma
    Abstract Number: 1770
    Session: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Poster I
    Date and Time: Saturday, December 6, 2014: 5:30 PM-7:30 PM PT
    Location: West Building, Level 1
    Presenter: Changchun Deng, MD, PhD
    Title: The PI3K-delta Inhibitor TGR-1202 In Combination with Brentuximab Vedotin (SGN-35) Synergistically Inhibits Tubulin Polymerization and Exerts Potent Antitumor Effects in NOD/SCID Mice with Hodgkin Lymphoma Cell Line Xenografts
    Abstract Number: 4486
    Session: 625. Lymphoma: Pre-Clinical - Chemotherapy and Biologic Agents: Poster III
    Date and Time: Monday, December 8, 2014: 6:00 PM-8:00 PM PT
    Location: West Building, Level 1
    Presenter: Silvia L. Locatelli, PhD

    Sentiment: Strong Buy

  • pharmatheway pharmatheway Dec 5, 2014 4:14 PM Flag

    Please don't feed the animals .The ignore option works great.See you monday ,have a good weekend .

    Sentiment: Strong Buy

  • Reply to

    SAVE THE WHALES

    by iamgarce Dec 5, 2014 11:02 AM
    pharmatheway pharmatheway Dec 5, 2014 3:47 PM Flag

    PRINCETON, N.J.--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE:BMY) today announced that study results on investigational agents Opdivo (nivolumab), a PD-1 immune checkpoint inhibitor, elotuzumab, an antibody targeted against Signaling Lymphocyte Activation Molecule (SLAMF7), ulocuplumab, an anti-CXCR4 antibody, and Sprycel (dasatinib), will be featured in oral presentations at the 56th annual meeting of the American Society for Hematology (ASH) in San Francisco from December 6-9, 2014. Data will be presented in multiple hematologic malignancies, including Hodgkin lymphoma (HL), non-Hodgkin lymphoma, multiple myeloma, chronic-phase chronic myeloid leukemia (CP-CML), acute myeloid leukemia (AML) and T-Cell acute lymphoblastic leukemia. In May 2014, the U.S. Food and Drug Administration (FDA) granted Opdivo its first Breakthrough Therapy Designation for the treatment of patients with HL after failure of autologous stem cell transplant and brentuximab.

    “The breadth of data we are presenting at ASH this year, including data on ulocupumab and findings from our immuno-oncology development programs for Opdivo and elotuzumab, underscores our commitment to research and development in hematology and to improving outcomes for patients across a range of blood cancers,” said Michael Giordano, senior vice president, Head of Development, Oncology, Bristol-Myers Squibb.

    Opdivo (nivolumab) Oral Presentations in HL and Lymphoid Malignancies

    Data on Opdivo, an investigational PD-1 immune checkpoint inhibitor, will be presented during two oral presentations on Monday, December 8. At 7:00 a.m. PST, preliminary efficacy, safety and biomarker results will be presented from the relapsed or refractory HL cohort of CheckMate - 039, a Phase 1 dose escalation study of patients with relapsed or refractory hematologic malignancies (Abstract #289). At 7:30 a.m. PST, additional results from CheckMate-039 will be presented, including patients with relapsed or refractory non-Hodgkin lymphoma (Abstract#291).

    Elotuzumab Oral Presentation in Multiple Myeloma

    Final results from the Phase 1b/2 study of elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma will be presented in an oral session on Monday, December 8 at 7:15 a.m. PST (Abstract #302).

    In May 2014, the FDA granted elotuzumab Breakthrough Therapy Designation for use in combination with one of the commonly used chemotherapy treatments for multiple myeloma (lenalidomide, used in combination with dexamethasone) in patients who have received one or more prior treatments.

    Sprycel (dasatinib) Oral Presentations in CP-CML

    Results from two Sprycel studies will be highlighted in oral presentations, including five-year data from the Phase 3 trial, DASISION, comparing Sprycel to Gleevec® *(imatinib mesylate) in newly diagnosed CP-CML patients on Sunday, December 7 at 4:45 p.m. PST (Abstract #152) and seven-year data from a Phase 3 study of patients with Gleevec-resistant or intolerant CP-CML on Monday, December 8 at 3:30 p.m. PST (Abstract #520).

    * Gleevec is a registered trademark of Novartis AG

    Additional Data Presentations

    Results from a Phase 1 study in relapsed/refractory AML, including safety, tolerability and clinical activity of the investigational anti-CXCR4 antibody ulocuplumab will be presented for the first time during an oral presentation on Monday, December 8 at 10:45 a.m. PST (Abstract #386). Additionally, results from a Phase 1 study of the safety and activity of BMS-906024, a notch inhibitor, in patients with relapsed T-Cell acute lymphoblastic leukemia, will be presented during a poster session on Saturday, December 6 between 5:30 and 7:30 p.m. PST (Abstract # 968).

    Sentiment: Strong Buy

SNTA
2.80-0.06(-2.10%)Dec 19 4:00 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.